UNASSIGNED: 61 Background: The global incidence of @entity157 is over 700,000 @entity1 making it the sixth leading @entity5 . Recently new drugs have been approved to treat @entity157 . Nevertheless, prognosis is poor with a 5 year survival of 11%. Hence, it is important to understand if there are differences in @entity3012 in the Real World (RWE) based on @entity1 demographics, comorbidities and whether current treatments are effective. METHODS: A robust global database of @entity157 @entity1 was constructed from @entity1 chart data with nearly 4,000 unique @entity1 records from the United States, the European Union, and Asia in 2011. Several hypotheses were tested including the impact of ethnicity, presence of Hep B or C or @entity82 , stage at diagnosis and/or if current treatments used could predict PFS and /or @entity3012 . CART and CHAID analyses were conducted to help determine @entity1 segments and treatment flows in conjunction with Kaplan-Meier plots to understand the differences in survival based key @entity1 and treatment attributes. RESULTS: One year survival appears to be associated with geography as it is significantly lower in China/ Korea compared to the United States and the European Union. Significantly higher one year survival rates are observed for @entity157 @entity1 in the European Union and the United States receiving @entity3375 compared with @entity1 receiving @entity2857 first line. However, in Asia there are no differences. Across all three regions @entity2857 use does not effect @entity3012 in Stage IV @entity1 . Further, no significant differences in one year survival are seen in @entity1 with Hep C or B or @entity82 compared to those with no history of @entity409 . @entity2857 treatment duration in China appears to be substantially lower. Finally, @entity1 -Pugh C @entity1 had lower survival compared to @entity1 -Pugh A or B @entity1 . CONCLUSIONS: Early diagnosis, intervention and treatment of @entity157 appear to be important predictors of survival. Stratifying groups by type of drug treatment including @entity2857 use does not appear to have a measurable effect on @entity3012 . Efforts aimed towards screening, early detection and treatment initiation during early stages to improve RWE for @entity157 @entity1 may be more effective than expanding treatment with @entity2857 in late stage @entity1 . Given the lack of significance in @entity3012 for late stage @entity1 treated with @entity2857 across the globe, serious thought should be given its use for late stage @entity1 .

Effectiveness of XXXX treatments in real-world experiences.

@entity1 :: ('9606', 'Species') :: ['Child', 'patients', 'patient'] @entity3375 :: ('6868', 'Gene') :: ['TACE'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib', 'Sorafenib'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC']
@entity157 :: (MESH:D006528,Disease) :: ['HCC']
